Testing a new treatment for early-stage memory loss and thinking problems

This trial is testing a medication called Trontinemab to see if it can help people in the early stages of Alzheimer's disease—when memory and thinking problems are just beginning. Half of the participants will receive the medication through an IV (a small tube in the arm), and half will receive a placebo (a saltwater solution with no active drug). Researchers will track how well the medication works and whether it is safe.

Alzheimer's disease damages the brain gradually, and there are currently few treatments that can slow this damage in its earliest stages. This trial exists to see whether this new medication can help people before their memory loss becomes severe.